American Healthcare REIT (AHR) Stock Overview
A Maryland-based self-managed REIT, owns and operates a diversified portfolio of clinical healthcare real estate across the U.S., U.K., and the Isle of Man. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
AHR Community Fair Values
See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
American Healthcare REIT, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.52 |
| 52 Week High | US$54.67 |
| 52 Week Low | US$35.46 |
| Beta | 0.81 |
| 1 Month Change | -7.20% |
| 3 Month Change | -3.30% |
| 1 Year Change | 29.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 251.89% |
Recent News & Updates
AHR: Equity Offering And Strong Q1 Performance Will Support Future Returns
Analysts have kept their fair value estimate for American Healthcare REIT steady at about $58.85 per share, while modestly adjusting assumptions around the discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s long term financial profile. What’s in the News for American Healthcare REIT American Healthcare REIT priced an underwritten public offering of 14,000,000 common shares at about US$50.005 per share, with expected gross proceeds of roughly US$705.6m before expenses, and a 30 day option for underwriters to buy an additional 2,100,000 shares.AHR: Equity Offering And Lower Impairments Will Support Future Earnings
Narrative Update on American Healthcare REIT The analyst price target for American Healthcare REIT has shifted modestly to about $58.85 from roughly $58.08, with analysts pointing to small adjustments in the discount rate, profit margin expectations, and future P/E assumptions to support the new view. What’s in the News American Healthcare REIT priced an underwritten public offering of 14,000,000 common shares, expected to generate approximately US$705.6 million in gross proceeds, with BofA Securities as underwriter and a 30 day option to purchase an additional 2,100,000 shares.Recent updates
Shareholder Returns
| AHR | US Health Care REITs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -3.3% | 1.4% |
| 1Y | 29.7% | 26.8% | 25.7% |
Return vs Industry: AHR exceeded the US Health Care REITs industry which returned 26.2% over the past year.
Return vs Market: AHR exceeded the US Market which returned 25.1% over the past year.
Price Volatility
| AHR volatility | |
|---|---|
| AHR Average Weekly Movement | 4.0% |
| Health Care REITs Industry Average Movement | 3.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AHR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AHR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 121 | Jeff Hanson | www.americanhealthcarereit.com |
American Healthcare REIT, Inc., a Maryland-based self-managed REIT, owns and operates a diversified portfolio of clinical healthcare real estate across the U.S., U.K., and the Isle of Man. Its focus includes senior housing, skilled nursing facilities (SNFs), outpatient medical (OM) buildings, and other healthcare-related properties. The company utilizes a fully integrated management platform and operates senior housing under the RIDEA structure.
American Healthcare REIT, Inc. Fundamentals Summary
| AHR fundamental statistics | |
|---|---|
| Market cap | US$9.06b |
| Earnings (TTM) | US$100.32m |
| Revenue (TTM) | US$2.37b |
Is AHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AHR income statement (TTM) | |
|---|---|
| Revenue | US$2.37b |
| Cost of Revenue | US$1.92b |
| Gross Profit | US$446.80m |
| Other Expenses | US$346.48m |
| Earnings | US$100.32m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.52 |
| Gross Margin | 18.84% |
| Net Profit Margin | 4.23% |
| Debt/Equity Ratio | 43.9% |
How did AHR perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/20 16:14 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
American Healthcare REIT, Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anthony Powell | Barclays |
| Juan Sanabria | BMO Capital Markets Equity Research |
| John Kim | BMO Capital Markets Equity Research |